Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
NCT01179399
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Nonhematological Malignancies
Interventions
DRUG:
TAK-960
Sponsor
Millennium Pharmaceuticals, Inc.